GSK Selects Genedata Biologics as Antibody Discovery Platform - - BioPharm International

ADVERTISEMENT

GSK Selects Genedata Biologics as Antibody Discovery Platform



Genedata, a provider of software solutions for drug discovery and life science research, reported that Biopharm R&D at GlaxoSmithKline (GSK) has selected Genedata Biologics as a R&D data management and workflow-support platform. The Genedata Biologics platform will support multiple GSK Biopharm R&D groups including lead identification and screening, protein optimization and engineering, and protein production.

The system can record, manage, and process data from GSK's antibody discovery platforms such as phage and yeast display, hybridoma, and other technologies. Genedata reports that the system can help to improve data quality, improve efficiency through upload and export of instrument data, and increase experimental throughput. Genedata and GSK will work together to support new discovery technologies and next-generation antibody formats.

Source: Genedata

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
AbbVie's Acquisition of Shire Could Save $8 Billion in Taxes
July 21, 2014
AstraZeneca Reveals Design for New Global R&D Center and Corporate Headquarters
July 18, 2014
AbbVie to Acquire Shire for $54.7 Billion
July 18, 2014
Particulate Matter Prompts Baxter's Recall of IV Solutions
July 17, 2014
Author Guidelines

Click here